PO.BCS01.08 · 生物信息与计算

用于空间蛋白质组学的通用AI基础模型

A general-purpose AI foundation model for spatial proteomics

海报缩略图:用于空间蛋白质组学的通用AI基础模型
编号 4163 展板 13 时间 4/21 09:00–12:00 区域 Section 3 主讲 Andrew Song, PhD
分会场 Digital Pathology 3
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Andrew H. Song1, Anurag Vaidya2, Muhammad Shaban1, Yuzhou Chang1, Huaying Qiu1, Yao Y. Yeo1, Guillaume Jaume1, Wenrui Wu1, Qin Ma3, Sizun Jiang1, Faisal Mahmood1

1Harvard Medical School, Boston, MA,2Massachusetts Institute of Technology, Cambridge, MA,3The Ohio State University, Columbus, OH

摘要 Abstract

中文摘要
用于生物标志物发现的标准空间蛋白质组学(SP)流程传统上依赖于细胞分割,随后进行单标志物阈值处理或基于规则的机制来分配细胞表型。然而,这往往受制于繁琐的人工标注过程,并且忽视了以多个标志物协调表达为特征、随细胞空间组织而变化的细胞状态。此外,由于假设生成和检验的迭代性质,将预处理后的细胞转化为队列层面可操作的生物学见解十分耗时。我们力图构建一个在大量空间蛋白质组学数据集上训练的AI基础模型,以应对这些挑战,并以平台无关的方式进一步加速关键的空间生物学任务。 我们提出KRONOS,一个直接在无分割多重图像块上运行的空间蛋白质组学基础模型。KRONOS将已在多个病理学基础模型中被证明成功的自监督学习方案扩展到空间蛋白质组学,采用能够灵活处理可变数量蛋白标志物的Vision Transformer架构,并同时编码蛋白表达水平和蛋白已知的生物学特性。KRONOS的训练数据集由4700万个单标志物图像块组成,涵盖175种蛋白标志物、16种组织类型、8个基于荧光的成像平台,来自5个不同机构。这一多样化的大规模数据集使KRONOS能够学习丰富的低维图像表征,有效地跨不同标志物联合捕获空间蛋白表达。 我们在多种下游任务中评估KRONOS,包括细胞表型分析、组织伪影检测和患者分层,涵盖淋巴瘤、肾细胞癌和皮肤癌等多种疾病类型。在这些任务中,KRONOS始终优于其他病理学(UNI)和空间蛋白质组学基础模型(CA-MAE)基线,凸显了在大型数据语料库上训练的领域特异性模型的重要性。特别是在细胞表型分析方面,我们展示了KRONOS具有数据高效性,仅需少量细胞标注,从而解决了空间蛋白质组学中的一个主要瓶颈——细胞层面标注生成成本高、速度慢且难以跨数据集复用。此外,KRONOS支持"反向图像搜索",用于在患者队列内部和之间识别相似的空间模式和生物学概念,促进临床相关肿瘤微环境和蛋白生物标志物的发现。总之,这些结果将KRONOS定位为一个用于空间蛋白质组学的通用基础模型,可简化分析、减轻标注负担,并为空间生物标志物发现开启新机遇。
查看英文原文 English abstract
Standard spatial proteomics (SP) pipelines for biomarker discovery have traditionally relied on cell segmentation followed by single-marker thresholding or rule-based mechanisms to assign cell phenotypes. However, this often suffers from a laborious process of manual annotations and neglects cell states characterized by the coordinated expression of multiple markers as a function of the cellular spatial organization. Moreover, converting the preprocessed cells to actionable biological insights on the cohort level is time-consuming due to its iterative nature of hypothesis generation and testing. We sought to build an AI foundation model trained on a large body of spatial proteomics datasets to address these challenges and further accelerate crucial spatial biology tasks in a platform-agnostic manner. We present KRONOS, a foundation model for spatial proteomics that operates directly on segmentation-free multiplex image patches. KRONOS extends the self-supervised learning recipe proven to be successful for several pathology foundation models to spatial proteomics, by employing a Vision Transformer architecture that can flexibly handle the variable number of protein markers and simultaneously encode the protein expression levels and the known biological properties of the protein. The training dataset for KRONOS consists of 47 million single-marker patches spanning 175 protein markers, 16 tissue types, eight fluorescence-based imaging platforms, across five different institutions. This diverse and large-scale dataset allows KRONOS to learn rich, low-dimensional image representations that effectively capture spatial protein expressions jointly across different markers. We evaluate KRONOS across a diverse range of downstream tasks, including cell phenotyping, tissue artifact detection, and patient stratification, and across diverse disease types such as lymphoma, renal cell carcinoma, and skin cancer. Across these tasks, KRONOS consistently outperforms other pathology (UNI) and spatial proteomics foundation model (CA-MAE) baselines, underscoring the importance of a domain-specific model trained on a large corpus of data. Specifically for cell phenotyping, we show that KRONOS is data-efficient and requires only a few cell annotations, addressing a major bottleneck in spatial proteomics where cell-level annotations are expensive to produce, slow to generate, and difficult to reuse across datasets. Furthermore, KRONOS allows “reverse image search” for identifying similar spatial patterns and biological concepts within and across patient cohorts, facilitating the discovery of clinically relevant tumor microenvironments and protein biomarkers.Together, these results position KRONOS as a general-purpose, foundation model for spatial proteomics that streamlines analysis, reduces annotation burden, and unlocks new opportunities for spatial biomarker discovery.
利益披露 Disclosure
A. H. Song, None.. A. Vaidya, None.. M. Shaban, None.. Y. Chang, None.. H. Qiu, None.. Y. Y. Yeo, None.. G. Jaume, None.. W. Wu, None.. Q. Ma, None. S. Jiang, Elucidate bio g., Board of Directors, non-salaried role), Stock, Stock Option. Roche ). Novartis ). F. Mahmood, Modella AI g., Board of Directors, non-salaried role), Stock, Stock Option. Danaher Advisory board.

← 返回 AACR 2026 检索